artios header image

News & Events

More exciting press coverage following $153 Million financing – Series C

27 August 2021 | Media coverage

featured-lg

Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X

27 July 2021 | Press release

nasdaq-2-400×400

Exciting press coverage following our Polθ (Pol-theta) press release – Nature Communications

1 July 2021 | Media coverage

Article-1-1-400×400

Our press coverage following our Novartis collaboration

1 July 2021 | Media coverage

Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Polθ Polymerase Inhibitor in Nature Communications

17 June 2021 | Press release

Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies

7 April 2021 | Press release

Artios Pharma to Attend Upcoming Conferences in February and March 2021

18 February 2021 | Press release

Niall Martin, Chief Executive Officer presented a company overview at LifeSci Partners Precision Oncology Day

17 February 2021 | Conferences

lifesci

Dr Graeme Smith presents at Medicine at The Crick – 11 February 2021

11 February 2021 | Conferences

tfci-1-400×400

Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients

11 February 2021 | Press release

image1-400×400

« Previous 1 2 3 4 5 Next »

© Artios Pharma 2022 | Website by Granite 5

Terms & conditions | Privacy policy | Site map